{"entity":{"id":"ottimo-pharma","kind":"company","name":"Ottimo Pharma","aka":[],"tldr":"Ottimo Pharma is testing a single antibody that both releases an immune brake (PD-1) and blocks a growth signal tumours use to build blood vessels (VEGFR2). It began its first human trial in the United States and Australia in early 2026.","summary":"Ottimo Pharma is a UK-registered company co-founded by Medicxi and Jonny Finlay that emerged from stealth in October 2024 under chief executive David Epstein. Its lead, jankistomig (OTP-01), is an Fc-null IgG1 antibody with a dual-paratopic design that engages the PD-1 immune checkpoint and the VEGFR2 angiogenic receptor in one conventional antibody. The FDA cleared its IND, and on 7 January 2026 the company reported the first patient dosed in a phase 1/2a open-label adaptive study in the US and Australia, initially enrolling patients with cancers known to benefit from PD-1 or VEGF treatment. In December 2024 it raised more than USD 140 million in a Series A led by OrbiMed, Avoro Capital and Samsara BioCapital.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://ottimopharma.com/"},{"label":"Emergence from stealth, October 2024","url":"https://ottimopharma.com/ottimo-pharma-emerges-from-stealth-with-backing-from-medicxi-and-management-team-led-by-david-epstein-to-accelerate-development-of-a-novel-pd1-vegfr2-bi-functional-antibody-planned-to-enter-the-clinic/"},{"label":"Series A of over USD 140 million, December 2024","url":"https://ottimopharma.com/ottimo-pharma-raises-over-140-million-in-series-a-financing/"},{"label":"IND clearance and first patient dosed, January 2026","url":"https://ottimopharma.com/fda-nda-clearance-otp-01/"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["bispecific-antibody","monoclonal-antibody"],"targets":["pd1","vegf"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07266428"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated; the company says it emerged from stealth in October 2024. Releases are datelined London and Boston, so the London headquarters is inferred from the UK registration. The company release gives no NCT number; the corpus trial NCT07266428, sponsored by Ottimo Pharma Limited and testing OTP-01, is linked as that study. VEGFR2 has no separate target record, so the combined VEGF/VEGFR record is linked."],"hq":"London","country":"GB","companyType":"biotech","website":"https://ottimopharma.com/","stage":"startup","investors":["medicxi","orbimed","samsara-biocapital"],"funding":[{"round":"Series A","year":2024,"amountUsd":140000000,"source":"https://ottimopharma.com/ottimo-pharma-raises-over-140-million-in-series-a-financing/","note":"Stated as 'over $140 million'; led by OrbiMed, Avoro Capital and Samsara BioCapital"}]},"route":"/companies/ottimo-pharma/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"trial":[{"id":"nct07266428","kind":"trial","name":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","route":"/trials/nct07266428/"}],"company":[{"id":"medicxi","kind":"company","name":"Medicxi","route":"/companies/medicxi/"},{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"},{"id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","route":"/companies/samsara-biocapital/"}]}}